Open in Screener

PBYI

Puma Biotechnology Inc

Jun 15 • 04:00PM ET

7.07

-0.26 -3.55 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: NKTR KROS INCY VKTX BMRN KRYS RYTM AXSM MDGL NBIX

| Held by: AVUV VTI IWM VXF IWN VTWO BSVO FESM DFAT DFAS

Index	RUT	P/E	14.81	EPS (ttm)	0.48	Insider Own	23.49%	Shs Outstand	50.88M	Perf Week	3.21%
Market Cap	359.86M	Forward P/E	35.35	EPS next Y	0.20	Insider Trans	-1.11%	Shs Float	38.94M	Perf Month	-1.67%
Enterprise Value	272.17M	PEG	-	EPS next Q	0.04	Inst Own	66.69%	Short Float	9.77%	Perf Quarter	16.47%
Income	24.38M	P/S	1.58	EPS this Y	-52.46%	Inst Trans	6.38%	Short Ratio	14.67	Perf Half Y	23.39%
Sales	227.18M	P/B	2.80	EPS next Y	-31.03%	ROA	12.54%	Short Interest	3.80M	Perf YTD	18.82%
Book/sh	2.52	P/C	3.47	EPS next 5Y	-	ROE	21.62%	52W High	7.90 -10.49%	Perf Year	111.04%
Cash/sh	2.04	P/FCF	6.71	EPS past 3/5Y	- -	ROIC	18.34%	52W Low	3.03 133.33%	Perf 3Y	99.15%
Dividend Est.	-	EV/EBITDA	6.78	Sales past 3/5Y	0.05% 0.29%	Gross Margin	74.46%	Volatility	4.49% 3.76%	Perf 5Y	-33.18%
Dividend TTM	-	EV/Sales	1.20	EPS Y/Y TTM	-37.13%	Oper. Margin	12.98%	ATR (14)	0.29	Perf 10Y	-78.07%
Dividend Ex-Date	-	Quick Ratio	2.24	Sales Y/Y TTM	-2.38%	Profit Margin	10.73%	RSI (14)	48.88	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.38	EPS Q/Q	-223.83%	SMA20	0.12%	Beta	1.20	Target Price	5.00
Payout	0.00%	Debt/Eq	0.12	Sales Q/Q	-2.59%	SMA50	-2.52%	Rel Volume	0.68	Prev Close	7.33
Employees	179	LT Debt/Eq	0.04	Earnings	May 07 AMC	SMA200	16.01%	Avg Volume	259.32K	Price	7.07
IPO	Apr 20, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	58.82% 6.67%	Trades		Volume	177,367	Change	-3.55%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-28-21	Upgrade	Citigroup	Neutral → Buy	$11
Jun-25-20	Resumed	BofA/Merrill	Underperform	$9
Oct-08-19	Downgrade	Goldman	Neutral → Sell	$24 → $8
May-10-19	Downgrade	Citigroup	Buy → Neutral	$24
May-10-19	Downgrade	Cantor Fitzgerald	Overweight → Neutral	$57 → $20
Jan-17-19	Initiated	Leerink Partners	Mkt Perform	$21
Jan-03-19	Downgrade	Guggenheim	Buy → Neutral
Nov-19-18	Upgrade	Goldman	Sell → Neutral
Nov-02-18	Downgrade	JP Morgan	Neutral → Underweight
Nov-02-18	Downgrade	BofA/Merrill	Buy → Underperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight	$75
Sep-17-18	Initiated	Goldman	Sell	$42
May-11-18	Reiterated	Stifel	Buy	$95 → $87
Nov-10-17	Reiterated	RBC Capital Mkts	Sector Perform	$92 → $108
Nov-10-17	Reiterated	Citigroup	Buy	$156 → $164
Oct-02-17	Reiterated	Stifel	Buy	$110 → $130
Sep-11-17	Reiterated	Credit Suisse	Outperform	$118 → $136
Jul-10-17	Resumed	Leerink Partners	Outperform	$115
Jun-06-17	Reiterated	RBC Capital Mkts	Sector Perform	$60 → $88
May-25-17	Reiterated	RBC Capital Mkts	Sector Perform	$40 → $60

Show Previous Ratings

Jun-03-26 05:00PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-08-26 08:30AM	Puma Biotechnology, Inc. Q1 2026 Earnings Call Summary (Moby)
May-07-26 05:37PM	Puma Biotech: Q1 Earnings Snapshot (Associated Press)
04:05PM	Puma Biotechnology Reports First Quarter 2026 Financial Results (Business Wire)
May-06-26 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
04:15PM	Loading…
Apr-23-26 04:15PM	Puma Biotechnology to Host Conference Call to Discuss First Quarter 2026 Financial Results (Business Wire)
Apr-02-26 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-26 12:35PM	PBYI Q4 Earnings & Sales Beat Estimates, Stock Down on Weak 2026 View (Zacks) -25.00%
08:30AM	Puma Biotechnology, Inc. Q4 2025 Earnings Call Summary (Moby)
01:12AM	Puma Biotechnology Q4 Earnings Call Highlights (MarketBeat)
12:05AM	Puma Biotechnology Inc (PBYI) Q4 2025 Earnings Call Highlights: Revenue Growth and Strategic ... (GuruFocus.com)
Feb-26-26 06:45PM	Puma Biotech (PBYI) Q4 Earnings and Revenues Beat Estimates (Zacks)
05:15PM	Puma Biotech: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-24-26 07:30PM	Jazz Pharmaceuticals (JAZZ) Beats Q4 Earnings and Revenue Estimates (Zacks) +5.34%
04:15PM	Loading…
Feb-23-26 04:15PM	Puma Biotechnology to Present at TD Cowens 46th Annual Health Care Conference (Business Wire)
Feb-12-26 04:07PM	Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2025 Financial Results (Business Wire)
Feb-10-26 05:25PM	Exelixis (EXEL) Q4 Earnings and Revenues Beat Estimates (Zacks)
Feb-04-26 05:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-07-26 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-31-25 11:20AM	Up 91% in the Past Year, Is This Biotech Stock Red Hot or a Red Flag? (Barchart)
Dec-22-25 04:10PM	Puma Biotechnology Added to the NASDAQ Biotechnology Index (NBI) (Business Wire)
Dec-17-25 11:26AM	CRMD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Buy? (Zacks)
Dec-02-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +6.57%
Nov-27-25 11:58AM	IRWD vs. PBYI: Which Small-Cap Biotech Stock Is the Better Pick? (Zacks)
Nov-07-25 05:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +22.24% -21.04%
10:53AM	PBYI's Q3 Earnings & Revenues Beat Estimates, 2025 Sales View Raised (Zacks)
12:03AM	Puma Biotechnology Inc (PBYI) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Royalty ... (GuruFocus.com)
Nov-06-25 06:00PM	Puma Biotech (PBYI) Q3 Earnings and Revenues Top Estimates (Zacks)
04:55PM	Puma Biotech: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Loading…
04:05PM	Puma Biotechnology Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-05-25 05:20PM	Acadia Pharmaceuticals (ACAD) Q3 Earnings and Revenues Top Estimates (Zacks)
Oct-23-25 04:10PM	Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results (Business Wire)
Oct-09-25 05:06AM	CRISPR Therapeutics (CRSP) Surges 8.7%: Is This an Indication of Further Gains? (Zacks)
Oct-02-25 05:21PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-17-25 02:27PM	What Do Analysts Think About Puma Biotechnology (PBYI)? (Insider Monkey)
Sep-15-25 12:42PM	PBYI Surges 30% in 3 Months: How Should You Play the Stock? (Zacks)
Sep-04-25 05:25PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-02-25 04:07PM	Puma Biotechnology to Present at the H.C. Wainwright 27th Annual Global Investment Conference (Business Wire)
Sep-01-25 09:55AM	Puma Biotech (PBYI) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Aug-28-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Aug-13-25 09:15AM	Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue? (Zacks) +8.83%
Aug-12-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
09:15AM	Puma Biotechnology, Inc. (PBYI) Soars to 52-Week High, Time to Cash Out? (Zacks)
09:11AM	Barclays Maintains a Sell Rating on Puma Biotechnology (PBYI) With a $2 PT (Insider Monkey)
Aug-08-25 05:00PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +12.16% +31.44%
10:26AM	PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues (Zacks)
Aug-07-25 05:55PM	Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
04:56PM	Puma Biotech: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports Second Quarter Financial Results (Business Wire)
Aug-06-25 06:05PM	Adma Biologics (ADMA) Q2 Earnings and Revenues Beat Estimates (Zacks)
Jul-24-25 04:15PM	Puma Biotechnology to Host Conference Call to Discuss Second Quarter 2025 Financial Results (Business Wire)
Jul-15-25 08:31AM	Add These 4 Top-Ranked Liquid Stocks to Boost Portfolio Returns (Zacks)
Jul-14-25 09:40AM	Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? (Zacks)
Jul-10-25 08:50AM	Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors (Zacks)
Jul-08-25 10:31AM	Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease (Zacks)
Jul-04-25 08:35AM	AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer (Zacks)
Jul-02-25 05:03PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
08:34AM	Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek (Zacks)
Jul-01-25 11:55AM	RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance (Zacks)
10:05AM	ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B (Zacks)
Jun-30-25 10:40AM	Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why (Zacks)
Jun-27-25 10:58AM	PFE's Hympavzi Phase III Hemophilia Study With Inhibitors Meets Goal (Zacks)
09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks)
Jun-25-25 11:30AM	NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study (Zacks)
Jun-24-25 08:50AM	Fast-paced Momentum Stock Puma Biotech (PBYI) Is Still Trading at a Bargain (Zacks)
Jun-19-25 11:11AM	Incyte Gets FDA Nod for the Expanded Use of Monjuvi in Lymphoma (Zacks)
Jun-18-25 10:51AM	Bayer Seeks FDA Approval for MRI Contrast Agent Gadoquatrane (Zacks)
Jun-12-25 11:30AM	Why Is Exelixis (EXEL) Down 7.2% Since Last Earnings Report? (Zacks)
Jun-11-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Jun-04-25 05:33PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +7.39%
May-28-25 08:50AM	Why Fast-paced Mover Puma Biotech (PBYI) Is a Great Choice for Value Investors (Zacks)
May-26-25 09:40AM	Are Investors Undervaluing Puma Biotechnology (PBYI) Right Now? (Zacks)
May-12-25 08:50AM	Despite Fast-paced Momentum, Puma Biotech (PBYI) Is Still a Bargain Stock (Zacks)
May-09-25 09:40AM	Is Puma Biotechnology (PBYI) Stock Undervalued Right Now? (Zacks) -5.21%
08:48AM	PBYI Stock Rises as Q1 Earnings and Sales Beat Estimates (Zacks)
03:39AM	Puma Biotechnology Inc (PBYI) Q1 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges (GuruFocus.com)
May-08-25 05:55PM	Puma Biotech (PBYI) Q1 Earnings and Revenues Top Estimates (Zacks)
04:52PM	Puma Biotech: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	Puma Biotechnology Reports First Quarter Financial Results (Business Wire)
May-07-25 05:20PM	Puma Biotechnology Q1 2025 Earnings Preview (Seeking Alpha)
01:25PM	Perrigo Q1 Earnings Beat Estimates, Revenues Decline Y/Y (Zacks)
11:55AM	JAZZ Misses Q1 Earnings & Sales Estimates, Cuts '25 EPS Outlook (Zacks)
08:10AM	Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
May-06-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-05-25 09:15AM	ANI Pharmaceuticals, Inc. (ANIP) Hit a 52 Week High, Can the Run Continue? (Zacks)
May-01-25 08:05AM	Biogen Inc. (BIIB) Q1 Earnings Lag Estimates (Zacks)
Apr-30-25 12:00PM	Puma Biotech (PBYI) Upgraded to Strong Buy: Here's What You Should Know (Zacks)
06:00AM	Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX (neratinib) for Breast Cancer Patients (GlobeNewswire)
Apr-28-25 03:03PM	Puma Biotechnology Presents Clinical Data on Neratinib at the AACR Annual Meeting 2025 (Business Wire)
Apr-24-25 04:11PM	Puma Biotechnology to Host Conference Call to Discuss First Quarter 2025 Financial Results (Business Wire)
Apr-23-25 09:40AM	Should Value Investors Buy Puma Biotechnology (PBYI) Stock? (Zacks)
Apr-21-25 09:13AM	Is the Options Market Predicting a Spike in Puma Biotechnology Stock? (Zacks)
Apr-11-25 01:20PM	Puma Biotechnology: Initiating Hold Rating With Limited Near-Term Upside And Uncertain Pipeline Potential (Seeking Alpha)
Apr-02-25 05:15PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-26-25 09:00AM	Puma Biotechnology to Present Clinical Data on Neratinib at the AACR Annual Meeting 2025 (Business Wire)
Mar-20-25 12:23PM	Puma Biotechnology Stock Rises 35% in 6 Months: Here's Why (Zacks)
Mar-18-25 04:35AM	Puma Biotechnology (PBYI): One of the Best Short-Term Stocks to Buy Right Now (Insider Monkey)
Mar-05-25 06:05PM	Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
05:30PM	Puma Biotechnology to Present at Barclays Annual Global Healthcare Conference (Business Wire)

Puma Biotechnology, Inc. is a biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. It focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. The company was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

FounderMr. Alan H. Auerbach

CFO & Principal Accounting OfficerMr. Maximo F. Nougues

FRAPSMr. Douglas Hunt B.Sc.

Chief Accounting OfficerMr. Gordon G. Esplin

Senior Director of Investor RelationsMr. Mariann Ohanesian

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WILSON TROY EDWARD	Director	Jun 12 '26	Sale	7.20	10,800	77,748	59,750	Jun 15 08:16 PM
Stuglik Brian M	Director	Jun 12 '26	Sale	7.20	8,100	58,311	113,858	Jun 15 08:14 PM
Senderowicz Adrian	Director	Jun 12 '26	Sale	7.20	27,000	194,311	27,000	Jun 15 08:13 PM
MOYES JAY M	Director	Jun 12 '26	Sale	7.22	22,000	158,796	58,322	Jun 15 08:10 PM
Dorval Allison	Director	Jun 12 '26	Sale	7.20	11,610	83,579	90,780	Jun 15 08:09 PM
Senderowicz Adrian	Director	Jun 12 '26	Proposed Sale	7.26	27,000	196,020		Jun 12 10:39 AM
MOYES JAY M	Director	Jun 12 '26	Proposed Sale	7.26	22,000	159,720		Jun 12 10:37 AM
Dorval Allison	Director	Jun 12 '26	Proposed Sale	7.26	11,610	84,289		Jun 12 10:33 AM
Stuglik Brian M	Director	Jun 12 '26	Proposed Sale	7.26	8,100	58,806		Jun 12 10:23 AM
WILSON TROY EDWARD	Director	Jun 12 '26	Proposed Sale	7.26	10,800	78,408		Jun 12 09:58 AM
AUERBACH ALAN H	President and CEO	Jan 07 '26	Sale	5.88	18,012	105,893	7,145,951	Jan 08 08:27 PM
AUERBACH ALAN H	President and CEO	Jan 06 '26	Sale	5.84	16,938	98,986	7,163,963	Jan 08 08:27 PM
HUNT DOUGLAS M	See Remarks	Jan 07 '26	Sale	5.88	5,014	29,477	155,907	Jan 08 08:15 PM
HUNT DOUGLAS M	See Remarks	Jan 06 '26	Sale	5.84	3,973	23,218	160,921	Jan 08 08:15 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jan 07 '26	Sale	5.88	6,405	37,655	193,284	Jan 08 08:14 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jan 06 '26	Sale	5.84	4,540	26,532	199,689	Jan 08 08:14 PM
AUERBACH ALAN H	Officer	Jan 07 '26	Proposed Sale	5.88	18,012	105,893		Jan 07 04:28 PM
HUNT DOUGLAS M	Officer	Jan 07 '26	Proposed Sale	5.88	5,014	29,477		Jan 07 04:25 PM
NOUGUES MAXIMO F	Officer	Jan 07 '26	Proposed Sale	5.88	6,405	37,655		Jan 07 04:24 PM
NOUGUES MAXIMO F	Officer	Jan 06 '26	Proposed Sale	5.84	4,540	26,530		Jan 06 04:53 PM
HUNT DOUGLAS M	Officer	Jan 06 '26	Proposed Sale	5.84	3,973	23,217		Jan 06 04:45 PM
AUERBACH ALAN H	Officer	Jan 06 '26	Proposed Sale	5.84	16,938	98,979		Jan 06 04:44 PM
MILLER MICHAEL PATRICK	Director	Nov 11 '25	Sale	4.86	20,000	97,228	54,000	Nov 13 04:41 PM
MILLER MICHAEL PATRICK	Director	Nov 11 '25	Proposed Sale	4.86	20,000	97,228		Nov 12 08:29 AM
Cesano Alessandra	Director	Jul 18 '25	Sale	3.37	27,000	90,909	41,850	Jul 22 07:51 PM
Cesano Alessandra	Director	Jul 18 '25	Proposed Sale	3.37	27,000	90,909		Jul 18 04:16 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jul 08 '25	Sale	3.53	5,587	19,739	208,164	Jul 10 08:56 PM
NOUGUES MAXIMO F	Chief Financial Officer	Jul 09 '25	Sale	3.54	3,935	13,910	204,229	Jul 10 08:56 PM
HUNT DOUGLAS M	See Remarks	Jul 08 '25	Sale	3.53	4,374	15,453	168,337	Jul 10 08:52 PM
HUNT DOUGLAS M	See Remarks	Jul 09 '25	Sale	3.54	3,443	12,171	164,894	Jul 10 08:52 PM
AUERBACH ALAN H	President and CEO	Jul 08 '25	Sale	3.53	25,592	90,417	7,202,481	Jul 10 08:49 PM
AUERBACH ALAN H	President and CEO	Jul 09 '25	Sale	3.54	21,580	76,285	7,180,901	Jul 10 08:49 PM
NOUGUES MAXIMO F	Officer	Jul 09 '25	Proposed Sale	3.54	3,935	13,910		Jul 09 04:48 PM
AUERBACH ALAN H	Officer	Jul 09 '25	Proposed Sale	3.54	21,580	76,285		Jul 09 04:36 PM
HUNT DOUGLAS M	Officer	Jul 09 '25	Proposed Sale	3.54	3,443	12,171		Jul 09 04:27 PM
AUERBACH ALAN H	Officer	Jul 08 '25	Proposed Sale	3.53	25,592	90,424		Jul 08 04:41 PM
NOUGUES MAXIMO F	Officer	Jul 08 '25	Proposed Sale	3.53	5,587	19,741		Jul 08 04:39 PM
HUNT DOUGLAS M	Officer	Jul 08 '25	Proposed Sale	3.53	4,374	15,455		Jul 08 04:29 PM

Open in Screener

VSTM

Verastem Inc

Jun 15 • 04:00PM ET

4.00

-0.10 -2.44 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: INCY KYMR NUVL BMRN RYTM VKTX KRYS AXSM MDGL NBIX

| Held by: VTI XBI IWM VXF FESM VTWO IWO IWN IWC VHT

Index	RUT	P/E	-	EPS (ttm)	-2.74	Insider Own	9.77%	Shs Outstand	87.84M	Perf Week	8.99%
Market Cap	351.49M	Forward P/E	-	EPS next Y	-1.07	Insider Trans	-0.21%	Shs Float	79.29M	Perf Month	-15.07%
Enterprise Value	255.28M	PEG	-	EPS next Q	-0.43	Inst Own	88.18%	Short Float	26.75%	Perf Quarter	-31.15%
Income	-193.96M	P/S	7.09	EPS this Y	48.67%	Inst Trans	0.02%	Short Ratio	9.12	Perf Half Y	-57.58%
Sales	49.59M	P/B	4.30	EPS next Y	30.70%	ROA	-107.90%	Short Interest	21.21M	Perf YTD	-48.19%
Book/sh	0.93	P/C	1.93	EPS next 5Y	41.17%	ROE	-786.15%	52W High	11.24 -64.43%	Perf Year	-28.57%
Cash/sh	2.07	P/FCF	-	EPS past 3/5Y	12.90% 10.63%	ROIC	-120.50%	52W Low	3.55 12.68%	Perf 3Y	-63.03%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- 10.80%	Gross Margin	82.91%	Volatility	7.34% 6.91%	Perf 5Y	-92.86%
Dividend TTM	-	EV/Sales	5.15	EPS Y/Y TTM	21.44%	Oper. Margin	-344.56%	ATR (14)	0.30	Perf 10Y	-76.02%
Dividend Ex-Date	-	Quick Ratio	3.00	Sales Y/Y TTM	395.85%	Profit Margin	-391.16%	RSI (14)	42.11	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.04	EPS Q/Q	61.29%	SMA20	-0.94%	Beta	0.28	Target Price	16.00
Payout	-	Debt/Eq	1.05	Sales Q/Q	-	SMA50	-19.78%	Rel Volume	0.99	Prev Close	4.10
Employees	102	LT Debt/Eq	0.97	Earnings	May 07 AMC	SMA200	-43.80%	Avg Volume	2.33M	Price	4.00
IPO	Jan 27, 2012	Option/Short	Yes / Yes	EPS/Sales Surpr.	20.43% -12.87%	Trades		Volume	2,313,643	Change	-2.44%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-12-26	Resumed	BTIG Research	Buy	$19
Feb-04-26	Initiated	H.C. Wainwright	Buy	$18
Oct-16-25	Resumed	Cantor Fitzgerald	Overweight
Apr-10-25	Initiated	Jefferies	Buy	$15
Mar-24-25	Reiterated	H.C. Wainwright	Buy	$7 → $10
Dec-31-24	Reiterated	BTIG Research	Buy	$13 → $20
Sep-30-24	Initiated	Guggenheim	Buy	$13
Nov-21-23	Resumed	BTIG Research	Buy	$27
Sep-27-23	Initiated	B. Riley Securities	Buy	$21
Jun-15-23	Upgrade	Mizuho	Neutral → Buy	$24 → $36
Sep-07-22	Resumed	Alliance Global Partners	Buy	$6
Apr-29-22	Resumed	Cantor Fitzgerald	Overweight	$6 → $5
Apr-14-22	Initiated	RBC Capital Mkts	Outperform	$5
Mar-09-22	Initiated	Truist	Buy	$6
Jul-01-21	Initiated	Alliance Global Partners	Buy	$6
May-24-21	Upgrade	BTIG Research	Neutral → Buy	$8
Jun-20-19	Downgrade	BTIG Research	Buy → Neutral
May-10-19	Downgrade	Raymond James	Outperform → Mkt Perform
Jul-13-18	Initiated	BTIG Research	Buy	$17
May-02-18	Initiated	Seaport Global Securities	Buy	$14

Show Previous Ratings

Jun-15-26 04:01PM	Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program (Business Wire)
Jun-03-26 08:10PM	VSTM Stock Climbs After-Hours As FDA Grants Fast Track To Lung Cancer Drug Retail Eyes The Next Keytruda (Stocktwits) +6.63%
May-27-26 07:30AM	Verastem Oncology to Present at Jefferies Healthcare Conference (Business Wire)
May-26-26 07:30AM	Verastem Oncology Appoints Michael P. Bailey to its Board of Directors (Business Wire)
May-12-26 07:30AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire) -5.12%
07:30AM	Loading…
May-08-26 07:30AM	On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer (Business Wire) -13.60%
May-07-26 05:16PM	Verastem: Q1 Earnings Snapshot (Associated Press) -5.82%
04:01PM	Verastem Oncology Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates (Business Wire)
Apr-30-26 07:30AM	Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI FAKZYNJA CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
Apr-23-26 07:30AM	Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026 (Business Wire)
Apr-10-26 07:00AM	Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI FAKZYNJA Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Womens Cancers (Business Wire) -5.01%
Apr-02-26 04:05PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-17-26 06:03PM	Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026 (Business Wire)
04:44PM	Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI FAKZYNJA (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women's Cancers (Business Wire)
Mar-05-26 08:30AM	Verastem, Inc. Q4 2025 Earnings Call Summary (Moby) +5.85%
12:03AM	Loading…
12:03AM	Verastem Inc (VSTM) Q4 2025 Earnings Call Highlights: Transition to Commercial Stage and ... (GuruFocus.com)
Mar-04-26 08:48PM	Verastem Q4 Earnings Call Highlights (MarketBeat)
05:10PM	Verastem (VSTM) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:20PM	Verastem: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
Feb-18-26 07:30AM	Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026 (Business Wire)
Feb-17-26 12:00PM	What Makes Verastem (VSTM) a New Buy Stock (Zacks)
Feb-16-26 01:02AM	Verastem Touts 50%+ Sales Growth for LGSOC Launch, Teases RAMP 301 and KRAS G12D Catalysts (MarketBeat)
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks) -7.51%
Feb-04-26 08:00AM	Here Are Wednesdays Top Wall Street Analyst Research Calls: AES Corp, Airbnb, Cloudflare, Devon Energy, Levi Strauss, Lumentum, PayPal, and More (24/7 Wall St.) +7.78%
07:30AM	Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers (Business Wire)
Jan-30-26 10:19AM	$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors (PR Newswire)
Jan-12-26 04:01PM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -8.73%
Jan-07-26 03:33PM	Revolution Medicines stock surges over 20% on potential AbbVie acquisition (Investing.com) +11.05%
Dec-29-25 04:01PM	Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer (Business Wire)
04:01PM	Loading…
Dec-15-25 04:01PM	Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth (Business Wire) -6.80%
Nov-25-25 07:30AM	Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference (Business Wire)
Nov-14-25 07:57AM	TEM Continues to Strengthen Its Genomics Leadership With New Products (Zacks) -6.84%
12:41AM	Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants (Business Wire)
Nov-13-25 04:07PM	Verastem Oncology Announces Proposed Public Offering of Common Stock (Business Wire)
Nov-05-25 07:30AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Nov-04-25 04:02PM	Verastem Inc (VSTM) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amidst Rising ... (GuruFocus.com) -20.10%
08:40AM	Verastem (VSTM) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
07:40AM	Verastem: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
Nov-03-25 12:00PM	Verastem (VSTM) Upgraded to Buy: Here's Why (Zacks)
Oct-29-25 11:57AM	Verastem, Inc. (VSTM) Delivers Positive Preliminary Data for VS-7375 in Mutant Solid Tumors Treatment (Insider Monkey)
Oct-28-25 11:35AM	3 Cancer-Focused Stocks Showing Strong Pipeline Progress (Zacks)
Oct-23-25 04:01PM	Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors (Business Wire)
09:55AM	Verastem (VSTM) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
07:30AM	Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025 (Business Wire)
Oct-21-25 10:00AM	Best Momentum Stocks to Buy for Oct. 21 (Zacks)
06:39AM	New Strong Buy Stocks for Oct. 21: NEM, AS and More (Zacks)
Oct-20-25 12:00PM	Are You Looking for a Top Momentum Pick? Why Verastem (VSTM) is a Great Choice (Zacks) -13.02%
09:55AM	Wall Street Analysts Think Verastem (VSTM) Could Surge 68.11%: Read This Before Placing a Bet (Zacks)
Oct-19-25 04:15AM	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma (Business Wire)
Oct-07-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-19-25 12:00PM	Verastem (VSTM) Upgraded to Buy: Here's What You Should Know (Zacks) -5.14%
Sep-16-25 01:13PM	Top Biotech Picks for 2025: BTIG Research Highlights Potential Winners (Investing.com) -7.03%
Aug-27-25 07:00AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Aug-17-25 03:22AM	Verastem Advances with Phase 3 Trial Progress and Product Launch Boosting Prospects (Insider Monkey)
Aug-13-25 04:29PM	Verastem Oncology Announces Late-Breaking Abstract from Partner GenFleet Therapeutics' Study in China of GFH375 (VS-7375) in Advanced Non-Small Cell Lung Cancer at IASLC 2025 World Conference on Lung Cancer (Business Wire)
Aug-07-25 06:40PM	Verastem (VSTM) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +19.93%
05:36PM	Verastem: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Verastem Oncology Reports Second Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
Aug-05-25 05:55PM	Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates (Zacks)
Jul-31-25 10:00AM	Earnings Preview: Verastem (VSTM) Q2 Earnings Expected to Decline (Zacks)
Jul-29-25 07:30AM	Verastem Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-24-25 07:30AM	Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer (Business Wire)
Jul-23-25 09:26AM	High-Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds (PR Newswire)
Jul-14-25 07:42AM	Verastems avutometinib combination shows 31% ORR in ovarian cancer trial (Clinical Trials Arena) +5.87%
Jul-11-25 04:12PM	Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology (Business Wire)
Jul-08-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-30-25 04:02PM	Verastem Oncology Announces Nature Medicine Publication of the Results from the First-in-Human Phase 1 FRAME Study of Avutometinib in Combination with Defactinib in Solid Tumors, including Low-Grade Serious Ovarian Cancer (Business Wire)
Jun-24-25 04:02PM	Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in a U.S. Phase 1/2a Trial in KRAS G12D Advanced Solid Tumors (Business Wire) -5.70%
Jun-20-25 08:41AM	Tempus AI's 89% Genomics Surge: Will the Momentum Keep Building? (Zacks) -5.01%
Jun-02-25 09:40AM	Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics' Phase 1 Study in China of GFH375 (VS-7375), an Oral KRAS G12D (ON/OFF) Inhibitor (Business Wire) -19.95%
May-28-25 10:43AM	VSTM Stock Soars 22% in a Month on Ovarian Cancer Combo Drug Approval (Zacks) -10.68%
07:30AM	Verastem Oncology to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-23-25 05:15PM	Verastem announces positive Phase 1/2 safety and efficacy results in PDAC (TipRanks) +11.10%
May-22-25 05:01PM	Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in Frontline Metastatic Pancreatic Ductal Adenocarcinoma (Business Wire)
May-20-25 11:39AM	Tempus partners with Verastem for companion diagnostic development (Medical Device Network)
08:30AM	Tempus Announces a Collaboration with Verastem to Develop CDx for First-Ever FDA-Approved KRAS-Mutant Recurrent Low-Grade Serous Ovarian Cancer Combination Treatment (Business Wire)
May-13-25 04:50PM	Verastem: Q1 Earnings Snapshot (Associated Press Finance)
04:34PM	Verastem Oncology Reports First Quarter 2025 Financial Results and Highlights Recent Business Updates (Business Wire)
May-09-25 11:55AM	FDA grants accelerated approval to avutometinib, defactinib combination (TipRanks)
May-08-25 02:47PM	FDA Grants Accelerated Approval To Verastem's Combination Drug For Ovarian Cancer (Benzinga)
01:17PM	FDA Approves the AVMAPKI FAKZYNJA Combination Therapy as the First-Ever Treatment for Adult Patients with KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer (Business Wire)
May-01-25 07:30AM	Verastem Oncology to Present at Upcoming Investor Conferences (Business Wire)
Apr-25-25 09:00AM	Verastem Oncology Announces $75 million Private Placement (Business Wire)
Apr-23-25 04:05PM	Verastem Oncology Announces U.S. IND Clearance of VS-7375, Oral KRAS G12D (ON/OFF) Inhibitor, Enabling Phase 1/2a Trial in Advanced Solid Tumors (Business Wire) +5.34%
Apr-22-25 10:39AM	Verastem Oncology to Report Q1 Earnings: What's in the Cards? (Zacks) +13.37%
Apr-16-25 09:45AM	Top Cancer Stocks to Buy to Boost Your Portfolio's Health (Zacks)
Apr-10-25 02:35PM	Verastem: RAMP-203 Study Could Be Next Big Win For Avutometinib Combination (Seeking Alpha) -14.39%
Apr-07-25 07:30AM	Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-27-25 09:55AM	Wall Street Analysts Believe Verastem (VSTM) Could Rally 100.94%: Here's is How to Trade (Zacks) +5.16%
Mar-25-25 04:35PM	Verastem Oncology Announces Multiple Presentations Focused on RAS/MAPK Pathway Inhibition at AACR Annual Meeting 2025 (Business Wire)
Mar-20-25 05:15PM	Verastem files to sell 1.42M shares of common stock by selling shareholders (SeekingAlpha)
04:17PM	Verastem: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates (Business Wire)
Mar-08-25 07:33AM	Why the Global Cancer Market Could Surpass $900 Billion--And the Stocks Leading the Charge (PR Newswire)
Feb-20-25 04:05PM	Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Womens Cancer (Business Wire)
Jan-29-25 07:30AM	Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference (Business Wire)
Jan-23-25 07:30AM	Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers (Business Wire)
Jan-15-25 07:30AM	Verastem Oncology Names Matthew E. Ros as Chief Operating Officer (Business Wire) +5.36%

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

PresidentMr. Daniel W. Paterson

Chief Financial OfficerMr. Daniel Calkins

Ph.D.Dr. Michael Glen Kauffman M.D.

Co-Founder & Chair of Scientific Advisory BoardDr. Robert A. Weinberg Ph.D.

Ph.D.Dr. Michelle Detwiler M.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gagnon Robert E.	Director	May 27 '26	Proposed Sale	4.36	20,103	87,649		May 27 04:47 PM
Paterson Dan	President and CEO	May 04 '26	Sale	5.82	806	4,691	612,113	May 06 04:01 PM
Paterson Dan	President and CEO	Feb 04 '26	Sale	6.69	970	6,489	612,919	Feb 05 04:10 PM
Dan Paterson	Officer	Jan 12 '26	Proposed Sale	7.16	5,039	36,069		Jan 14 05:15 PM
Dan Paterson	Officer, Director	Jan 12 '26	Proposed Sale	7.16	10,321	73,851		Jan 14 05:13 PM
Paterson Dan	President and CEO	Jan 12 '26	Sale	7.16	10,321	73,898	400,104	Jan 14 05:12 PM
Calkins Daniel	Chief Financial Officer	Jan 12 '26	Sale	7.16	5,039	36,079	104,719	Jan 14 05:11 PM
Calkins Daniel	Chief Financial Officer	Dec 24 '25	Sale	7.86	80	629	109,758	Dec 29 12:24 PM
Stuglik Brian M	Director	Dec 16 '25	Sale	9.14	592	5,411	101,147	Dec 18 04:47 PM
Paterson Dan	President and CEO	Dec 16 '25	Sale	9.14	393	3,592	410,425	Dec 18 04:46 PM
Gagnon Robert E.	Director	Dec 16 '25	Sale	9.14	283	2,587	41,678	Dec 18 04:45 PM
Paterson Dan	President and CEO	Dec 10 '25	Sale	10.07	2,000	20,140	412,818	Dec 12 05:06 PM
Paterson Dan	President and CEO	Dec 11 '25	Sale	10.00	2,000	20,000	410,818	Dec 12 05:06 PM
Paterson Dan	President and CEO	Dec 05 '25	Sale	10.61	2,000	21,220	418,818	Dec 09 05:03 PM
Paterson Dan	President and CEO	Dec 08 '25	Sale	10.50	2,000	21,000	416,818	Dec 09 05:03 PM
Paterson Dan	President and CEO	Dec 09 '25	Sale	10.25	2,000	20,500	414,818	Dec 09 05:03 PM
Paterson Dan	Officer	Dec 09 '25	Proposed Sale	10.27	7,790	80,003		Dec 09 03:11 PM
Paterson Dan	President and CEO	Dec 02 '25	Sale	10.32	2,000	20,640	424,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Dec 04 '25	Sale	10.00	2,000	20,000	420,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Dec 03 '25	Sale	10.00	2,000	20,000	422,818	Dec 04 04:54 PM
Paterson Dan	President and CEO	Nov 28 '25	Sale	10.79	2,000	21,580	428,818	Dec 01 04:40 PM
Paterson Dan	President and CEO	Dec 01 '25	Sale	10.39	2,000	20,780	426,818	Dec 01 04:40 PM
Paterson Dan	President and CEO	Nov 26 '25	Sale	10.32	2,000	20,640	430,818	Dec 01 04:40 PM
Bunn Paul A.	Director	Nov 21 '25	Option Exercise	3.27	6,250	20,438	8,333	Nov 25 05:35 PM
Bunn Paul A.	Director	Nov 21 '25	Sale	10.00	6,250	62,500	2,083	Nov 25 05:35 PM
Kauffman Michael	Director	Nov 21 '25	Sale	10.00	8,550	85,500	8,666	Nov 25 05:34 PM
Paterson Dan	President and CEO	Nov 25 '25	Sale	10.00	2,000	20,000	432,818	Nov 25 05:32 PM
Paterson Dan	President and CEO	Nov 24 '25	Sale	10.00	2,000	20,000	434,818	Nov 25 05:32 PM
Paterson Dan	President and CEO	Nov 21 '25	Sale	10.00	2,000	20,000	436,818	Nov 25 05:32 PM
Kauffman Michael	Board Member	Nov 21 '25	Proposed Sale	9.81	8,550	83,876		Nov 21 04:20 PM
Bunn Paul A.	Board Member	Nov 21 '25	Proposed Sale	9.81	6,250	61,312		Nov 21 04:10 PM
Paterson Dan	President and CEO	Nov 03 '25	Sale	9.74	3,299	32,146	438,818	Nov 06 12:21 PM
Bunn Paul A.	Director	Oct 09 '25	Sale	9.06	8,333	75,497	8,333	Oct 14 04:31 PM
Bunn Paul A.	Board Member	Oct 09 '25	Proposed Sale	8.94	8,333	74,497		Oct 09 04:05 PM
Calkins Daniel	Chief Financial Officer	Sep 22 '25	Sale	9.08	57	518	109,863	Sep 24 04:30 PM
Calkins Daniel	Chief Financial Officer	Sep 24 '25	Sale	9.23	25	231	109,838	Sep 24 04:30 PM
Stuglik Brian M	Director	Sep 16 '25	Sale	9.99	587	5,864	101,739	Sep 18 06:16 PM
Gagnon Robert E.	Director	Sep 16 '25	Sale	9.99	281	2,807	41,961	Sep 18 06:14 PM
Paterson Dan	President and CEO	Sep 16 '25	Sale	9.99	390	3,896	442,117	Sep 18 06:11 PM
Paterson Dan	Officer	Sep 17 '25	Proposed Sale	9.76	31,790	310,429		Sep 04 12:39 PM
Paterson Dan	President and CEO	Aug 06 '25	Sale	5.81	1,332	7,739	442,507	Aug 06 08:38 PM
Paterson Dan	President and CEO	Jun 20 '25	Sale	5.13	17,808	91,355	443,839	Jun 24 04:39 PM
Calkins Daniel	Chief Financial Officer	Jun 20 '25	Sale	5.13	4,110	21,084	109,945	Jun 24 04:37 PM
Calkins Daniel	Chief Financial Officer	Jun 23 '25	Sale	4.71	25	118	109,920	Jun 24 04:37 PM
Dan Paterson	Officer	Jun 20 '25	Proposed Sale	5.13	17,808	91,334		Jun 20 05:35 PM

PBYI

Puma Biotechnology Inc

VSTM

Verastem Inc

Upgrade your Finviz experience